Acadian Asset Management’s Pacira BioSciences PCRX Stock Holding History

Acadian Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,907	Closed	-$75K	–	2201
2025 Q4	$75K	Buy	2,907 +1,519	+109%	+$36.1K	﹤0.01%	1734
2025 Q3	$35K	Sell	1,388 -15,028	-92%	-$369K	﹤0.01%	1694
2025 Q2	$390K	Buy	+16,416	New	+$414K	﹤0.01%	1188
2020 Q2	–	Sell	-732	Closed	-$25K	–	2308
2020 Q1	$25K	Buy	+732	New	+$30.4K	﹤0.01%	1623
2019 Q4	–	Sell	-249	Closed	-$9K	–	2020
2019 Q3	$9K	Buy	+249	New	+$9.94K	﹤0.01%	1773
2019 Q2	–	Sell	-52,598	Closed	-$2M	–	1992
2019 Q1	$2M	Sell	52,598 -5,545	-10%	-$216K	0.01%	692
2018 Q4	$2.5M	Sell	58,143 -242	-0.4%	-$11.3K	0.01%	523
2018 Q3	$2.87M	Buy	+58,385	New	+$2.52M	0.01%	485
2016 Q2	–	Sell	-1,610	Closed	-$85K	–	1498
2016 Q1	$85K	Buy	+1,610	New	+$94.2K	﹤0.01%	1054

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management's PCRX Position: Q1 2026 in Review

Acadian Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 2,907 shares — an estimated $75K sold.

Acadian Asset Management first reported a position in PCRX in Q1 2016 and held it in 9 quarters. The position peaked at $2.87M in Q3 2018. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Acadian Asset Management reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Acadian Asset Management sold 2,907 Pacira BioSciences shares in Q1 2026, an estimated $75K.
Acadian Asset Management first reported a position in Pacira BioSciences in Q1 2016 and held it in 9 quarters.
Acadian Asset Management's Pacira BioSciences position peaked at $2.87M in Q3 2018.
242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.